Interaction of linear and cyclic peptide antagonists at the human B2 kinin receptor

被引:5
作者
Cucchi, P [1 ]
Meini, S
Quartara, L
Giolitti, A
Zappitelli, S
Rotondaro, L
Maggi, CA
机构
[1] Menarini Ric SpA, Dept Pharmacol, I-50135 Florence, Italy
[2] Menarini Ric SpA, Dept Chem, I-50135 Florence, Italy
[3] Menarini Ric SpA, Drug Design Dept, I-50135 Florence, Italy
[4] Menarini Biotech, Dept Biotechnol, Rome, Italy
关键词
bradykinin; bradykinin B-2 receptor; bradykinin antagonists; icatibant; MEN; 11270;
D O I
10.1016/S0196-9781(02)00081-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The ligand receptor interactions involving the C-terminal moiety of kinin B-2 receptor antagonists Icatibant (H-DArg-Arg-Pro-Hyp-Gly-Thi-Ser-Dtic-Oic-Arg-OH), MEN 11270 (H-DArg-Arg-Pro-Hyp-Gly-Thi-c(Dab-Dtic-Oic-Arg)c(7gamma-10alpha)) and a series of analogs modified in position 10 were investigated by radioligand-binding experiments at the wild type (WT) and at the Ser(111)Ala and Ser(111)Lys mutant human kinin B-2 receptors. Icatibant and [Lys(10)]-Icatibant maintained the same high affinity towards the three receptors. For Icatibant-NH2, [Ala(10)]-Icatibant, MEN 11270 and [Glu(10)]-MEN 11270, the changes in affinity at the WT and Ser(111)Lys receptors indicated that the presence of a net positive or negative charge at the C-terminal moiety of these peptides caused a decrease in affinity to the WT receptor and that Ser(111) residue is in proximity of the side chain of residue 10. The changes in affinity measured with [desArg(10)]-Icatibant and [desArg(10)]-Icatibant-NH2, moreover, confirmed that a C-terminal charge compensation between the positive charge of Arg(10) side chain and the C-terminal free carboxylic function favours a high affinity interaction. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1457 / 1463
页数:7
相关论文
共 21 条
[1]
Structure of the bradykinin B-2 receptors' amino terminus [J].
AbdAlla, S ;
Godovac-Zimmermann, J ;
Braun, A ;
Roscher, AA ;
MullerEsterl, W ;
Quitterer, U .
BIOCHEMISTRY, 1996, 35 (23) :7514-7519
[2]
ABDALLA S, 1996, J BIOL CHEM, V271, P1725
[3]
BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[4]
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]
A single position in the third transmembrane domains of the human B1 and B2 bradykinin receptors is adjacent to and discriminates between the C-terminal residues of subtype-selective ligands [J].
Fathy, DB ;
Mathis, SA ;
Leeb, T ;
Leeb-Lundberg, LMF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (20) :12210-12218
[7]
COMBINED APPROACH OF NMR AND MOLECULAR-DYNAMICS WITHIN A BIPHASIC MEMBRANE MIMETIC - CONFORMATION AND ORIENTATION OF THE BRADYKININ ANTAGONIST HOE-140 [J].
GUBA, W ;
HAESSNER, R ;
BREIPOHL, G ;
HENKE, S ;
KNOLLE, J ;
SANTAGADA, V ;
KESSLER, H .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1994, 116 (17) :7532-7540
[8]
The N terminus of bradykinin when bound to the human bradykinin B2 receptor is adjacent to extracellular Cys(20) and Cys(277) in the receptor [J].
Herzig, MCS ;
Nash, NR ;
Connolly, M ;
Kyle, DJ ;
LeebLundberg, LMF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (47) :29746-29751
[9]
CLONING AND PHARMACOLOGICAL CHARACTERIZATION OF A HUMAN BRADYKININ (BK-2) RECEPTOR [J].
HESS, JF ;
BORKOWSKI, JA ;
YOUNG, GS ;
STRADER, CD ;
RANSOM, RW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 184 (01) :260-268
[10]
HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x